[go: up one dir, main page]

CL2016002195A1 - Car chimeric antigen receptor with antigen binding domains to the constant region of the beta t cell receptor - Google Patents

Car chimeric antigen receptor with antigen binding domains to the constant region of the beta t cell receptor

Info

Publication number
CL2016002195A1
CL2016002195A1 CL2016002195A CL2016002195A CL2016002195A1 CL 2016002195 A1 CL2016002195 A1 CL 2016002195A1 CL 2016002195 A CL2016002195 A CL 2016002195A CL 2016002195 A CL2016002195 A CL 2016002195A CL 2016002195 A1 CL2016002195 A1 CL 2016002195A1
Authority
CL
Chile
Prior art keywords
receptor
constant region
beta
binding domains
antigen binding
Prior art date
Application number
CL2016002195A
Other languages
Spanish (es)
Inventor
Martin Pulé
Paul Maciocia
Original Assignee
Ucl Business Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52649058&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016002195(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB201403905A external-priority patent/GB201403905D0/en
Priority claimed from GB201416908A external-priority patent/GB201416908D0/en
Application filed by Ucl Business Plc filed Critical Ucl Business Plc
Publication of CL2016002195A1 publication Critical patent/CL2016002195A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • G01N33/57505—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)

Abstract

LA INVENCIÓN PROPORCIONA UN RECEPTOR ANTIGÉNICO QUIMÉRICO CAR CON DOMINIOS DE UNIÓN A ANTÍGENOS A LA REGIÓN CONSTANTE DEL RECEPTOR DE CÉLULAS T BETATHE INVENTION PROVIDES A CAR CHEMERIC ANTIGEN RECEIVER WITH UNION DOMAINS TO ANTIGENS TO THE CONSTANT REGION OF THE T BETA CELL RECEIVER

CL2016002195A 2014-03-05 2016-09-01 Car chimeric antigen receptor with antigen binding domains to the constant region of the beta t cell receptor CL2016002195A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201403905A GB201403905D0 (en) 2014-03-05 2014-03-05 Method
GB201416908A GB201416908D0 (en) 2014-09-25 2014-09-25 Method

Publications (1)

Publication Number Publication Date
CL2016002195A1 true CL2016002195A1 (en) 2017-05-19

Family

ID=52649058

Family Applications (4)

Application Number Title Priority Date Filing Date
CL2016002195A CL2016002195A1 (en) 2014-03-05 2016-09-01 Car chimeric antigen receptor with antigen binding domains to the constant region of the beta t cell receptor
CL2018003096A CL2018003096A1 (en) 2014-03-05 2018-10-30 Chimeric antigenic receptor (car) with antigen binding domains to the constant region of the beta t cell receptor (divisional of application 2195-2016).
CL2019001567A CL2019001567A1 (en) 2014-03-05 2019-06-07 Conjugate antibody that binds to the constant region of the beta 1 (trbc1) or trbc2 t-cell receptor. (divisional application 201803096)
CL2019001568A CL2019001568A1 (en) 2014-03-05 2019-06-07 A bispecific t-cell coupler comprising a first domain that binds to the constant region of tcr beta 1 (trbc1) or trbc2, and a second domain capable of activating a t cell. (divisional application 201803096)

Family Applications After (3)

Application Number Title Priority Date Filing Date
CL2018003096A CL2018003096A1 (en) 2014-03-05 2018-10-30 Chimeric antigenic receptor (car) with antigen binding domains to the constant region of the beta t cell receptor (divisional of application 2195-2016).
CL2019001567A CL2019001567A1 (en) 2014-03-05 2019-06-07 Conjugate antibody that binds to the constant region of the beta 1 (trbc1) or trbc2 t-cell receptor. (divisional application 201803096)
CL2019001568A CL2019001568A1 (en) 2014-03-05 2019-06-07 A bispecific t-cell coupler comprising a first domain that binds to the constant region of tcr beta 1 (trbc1) or trbc2, and a second domain capable of activating a t cell. (divisional application 201803096)

Country Status (24)

Country Link
US (2) US20170066827A1 (en)
EP (3) EP4610654A2 (en)
JP (5) JP6767872B2 (en)
KR (3) KR102088082B1 (en)
CN (4) CN106068276B (en)
AU (3) AU2015225944B2 (en)
BR (1) BR112016020304B1 (en)
CA (1) CA2940564C (en)
CL (4) CL2016002195A1 (en)
CU (1) CU24475B1 (en)
DK (2) DK3241561T3 (en)
ES (2) ES2758173T3 (en)
FI (1) FI3241561T3 (en)
HU (2) HUE071755T2 (en)
IL (3) IL278878B (en)
MX (3) MX2016010856A (en)
MY (1) MY173567A (en)
PE (2) PE20211887A1 (en)
PH (3) PH12020550202B1 (en)
PL (2) PL3125934T3 (en)
PT (2) PT3241561T (en)
RU (2) RU2021101502A (en)
SG (3) SG10201906461SA (en)
WO (1) WO2015132598A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11434293B2 (en) 2017-06-09 2022-09-06 Autolus Limited Anti TRBC1 antigen binding domains
US11879016B2 (en) 2014-03-06 2024-01-23 Autolus Limited Chimeric antigen receptor

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11385233B2 (en) 2015-03-05 2022-07-12 Autolus Limited Methods of depleting malignant T-cells
US11982672B2 (en) 2014-03-05 2024-05-14 Autolus Limited Methods
EP3868388A1 (en) 2014-10-03 2021-08-25 Oxford University Innovation Limited Analysis of t-cell monotypia
CA2937157A1 (en) 2016-07-25 2018-01-25 Ucl Business Plc Protein-based t-cell receptor knockdown
KR20250072712A (en) 2016-12-02 2025-05-26 앤젤레스 테라퓨틱스, 인코포레이티드 Synthetic immune receptors and methods of use thereof
EP4491234A3 (en) 2017-02-08 2025-04-09 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
DK3582806T5 (en) 2017-02-20 2024-09-02 Dragonfly Therapeutics Inc PROTEINS THAT BIND HER2, NKG2D, AND CD16
TWI704158B (en) * 2017-04-04 2020-09-11 瑞士商赫孚孟拉羅股份公司 Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap
EP3662055A1 (en) * 2017-08-02 2020-06-10 Autolus Limited Cells expressing a chimeric antigen receptor or engineered tcr and comprising a nucleotide sequence which is selectively expressed
AU2018322178A1 (en) * 2017-08-23 2020-02-20 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and a tumor-associated antigen
CA3086267A1 (en) * 2017-12-29 2019-07-04 Cellectis Method for improving production of car t cells
WO2019129850A1 (en) * 2017-12-29 2019-07-04 Cellectis Off-the-shelf engineered cells for therapy
GB201800298D0 (en) * 2018-01-09 2018-02-21 Autolus Ltd Method
WO2019139987A1 (en) 2018-01-09 2019-07-18 Elstar Therapeutics, Inc. Calreticulin binding constructs and engineered t cells for the treatment of diseases
WO2019143961A2 (en) * 2018-01-19 2019-07-25 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting gamma delta t cells with chimeric antigen receptors
US12384847B2 (en) 2018-02-08 2025-08-12 Dragonfly Therapeutics, Inc. Cancer therapy involving an anti-PD1 antibody and a multi-specific binding protein that binds NKG2D, CD16, and a tumor-associated antigen
EP3749346B1 (en) 2018-02-08 2024-07-10 Dragonfly Therapeutics, Inc. Antibody variable domain combinations targeting the nkg2d receptor
EP3755721A4 (en) 2018-02-20 2021-12-22 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
WO2019178362A1 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
DE202019005887U1 (en) 2018-07-03 2023-06-14 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
US20210283180A1 (en) * 2018-07-06 2021-09-16 The Arizona Board Of Regents On Behalf Of The University Of Arizona Car t cell therapy to target t cell specific cancers
US20210277120A1 (en) * 2018-07-18 2021-09-09 The General Hospital Corporation Compositions and methods for treatment of t cell malignancies
GB201812650D0 (en) * 2018-08-03 2018-09-19 Autolus Ltd Molecular assessment of TRBC usage
AU2019318087B2 (en) 2018-08-08 2025-09-18 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD 16 and a tumor-associated antigen
EA202091888A1 (en) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. VARIABLE ANTIBODY DOMAINS TARGETED ON THE NKG2D RECEPTOR
AR114544A1 (en) 2018-08-08 2020-09-16 Dragonfly Therapeutics Inc MULTI-SPECIFIC BINDING PROTEINS BINDING BCMA, NKG2D AND CD16, AND METHODS OF USE
GB201817172D0 (en) 2018-10-22 2018-12-05 Autolus Ltd Antibody
GB201817822D0 (en) * 2018-10-31 2018-12-19 Autolus Ltd Binding domain
CN113508137B (en) * 2019-01-29 2024-12-20 上海交通大学 Chimeric antigen receptor and its application
SG11202109033XA (en) * 2019-02-21 2021-09-29 Marengo Therapeutics Inc Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
AU2020224681A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
CN110317266A (en) * 2019-07-17 2019-10-11 东北农业大学 Three kinds of scFv antibody, its encoding gene and its application in the O-shaped hoof-and-mouth disease preparation of preparation treatment or prevention
CA3166629A1 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
EP4121518A4 (en) * 2020-03-16 2024-06-19 Marengo Therapeutics, Inc. MANIPULATED CELL COMPOSITIONS AND METHODS OF USE THEREOF
GB202004263D0 (en) * 2020-03-24 2020-05-06 Autolus Ltd Antibody conjugate
GB202005216D0 (en) 2020-04-08 2020-05-20 Autolus Ltd Cell
EP4132962A1 (en) 2020-04-09 2023-02-15 Autolus Limited Molecule
GB202101491D0 (en) 2021-02-03 2021-03-17 Autolus Ltd Molecule
JP2023523011A (en) * 2020-04-24 2023-06-01 マレンゴ・セラピューティクス，インコーポレーテッド Multifunctional molecules that bind to T cell-associated cancer cells and uses thereof
MX2022013944A (en) 2020-05-06 2022-11-30 Dragonfly Therapeutics Inc Proteins binding nkg2d, cd16 and clec12a.
CN111537735A (en) * 2020-05-15 2020-08-14 江西赛基生物技术有限公司 Antibody detection kit and application thereof in immunoassay
CN111549044B (en) * 2020-07-13 2020-10-23 北京市肿瘤防治研究所 Preparation method and application of CAR-T cells targeting TRBC1
EP4200401B1 (en) 2020-08-18 2024-07-24 Medigene Immunotherapies GmbH Enrichment of t cells using an anti-cbeta antibody
EP4204458A4 (en) * 2020-08-26 2024-10-09 Marengo Therapeutics, Inc. METHODS FOR DETECTING TRBC1 OR TRBC2
US20240124608A1 (en) * 2021-02-17 2024-04-18 The Johns Hopkins University Methods and materials for treating clonal t cell expansions
WO2022177870A1 (en) * 2021-02-17 2022-08-25 The Board Of Regents Of The University Of Texas System Multimeric sars-cov-2 binding molecules and uses thereof
WO2022187539A1 (en) 2021-03-03 2022-09-09 Dragonfly Therapeutics, Inc. Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen
GB202112923D0 (en) * 2021-09-10 2021-10-27 Ucl Business Ltd Binding domain
JPWO2024085182A1 (en) 2022-10-18 2024-04-25
WO2024236163A1 (en) 2023-05-17 2024-11-21 Morphosys Ag T cell receptor beta constant region 2 (trbc2) antibodies
WO2024256823A1 (en) 2023-06-14 2024-12-19 Autolus Limited Treatment of trbc1-positive t cell malignancies
AU2024305993A1 (en) * 2023-06-28 2026-01-15 The Johns Hopkins University Trbc targeting antibody-drug conjugates
GB202310981D0 (en) 2023-07-18 2023-08-30 Autolus Ltd Method
WO2025051339A1 (en) * 2023-09-05 2025-03-13 Tiber Biotech Srl SINGLE-CHAIN VARIABLE FRAGMENT AND MOLECULES DERIVING THEREFROM THAT BIND FRAGMENT TRVB5-1 OF THE β CHAIN OF HUMAN T-CELL RECEPTOR
WO2025096673A1 (en) * 2023-10-30 2025-05-08 The Board Of Trustees Of The Leland Stanford Junior University Compositions comprising cells targeting cancer and methods of using the same
WO2025202622A1 (en) * 2024-03-26 2025-10-02 Oxford University Innovation Limited Antibodies

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06502529A (en) * 1990-08-09 1994-03-24 ナショナル　ジューイッシュ　センター　フォア　イミュノロジィ　アンド　レスパラトリィ　メディスン Method for producing monoclonal antibodies against human T cell receptor elements using recombinant DNA vectors
US6790604B1 (en) * 1998-05-12 2004-09-14 Stefan A. Cohen Methods for identifying or diagnosing carcinoma cells with metastatic potential based on the measurement of lymphoid genes or their products in carcinoma cells
EP1497332A1 (en) * 2002-04-29 2005-01-19 GenPat77 Pharmacogenetics AG Bispecific antibody binding tcr and tirc7 and its use in therapy and diagnosis
RU2355703C2 (en) * 2002-10-09 2009-05-20 Медиджен Лимитед Single-strand recombinant t-cell receptors
GB0304068D0 (en) * 2003-02-22 2003-03-26 Avidex Ltd Substances
US7741045B2 (en) * 2006-11-16 2010-06-22 General Electric Company Sequential analysis of biological samples
WO2009151628A2 (en) * 2008-06-12 2009-12-17 Gov't Of The Usa, As Represented By The Secretary, Department Of Health Human Services Monitoring tcr-b to determine hiv therapy and disease progression
CA2735193A1 (en) * 2008-08-26 2010-03-11 Macrogenics, Inc. T-cell receptor antibodies and methods of use thereof
CN105693861A (en) * 2009-12-29 2016-06-22 新兴产品开发西雅图有限公司 Heterodimer binding protein and application thereof
JP6000507B2 (en) * 2010-09-30 2016-09-28 パナソニックヘルスケアホールディングス株式会社 Medical information registration device
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2013074916A1 (en) * 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
MA37681B2 (en) * 2012-05-25 2020-07-29 Cellectis Methods for modifying resistant allogeneic and immunosuppressive T cells for immunotherapy
US10443100B2 (en) * 2014-05-22 2019-10-15 The Scripps Research Institute Gene expression profiles associated with sub-clinical kidney transplant rejection
KR20170083534A (en) * 2014-09-19 2017-07-18 리제너론 파마슈티칼스 인코포레이티드 Chimeric antigen receptors
WO2016160721A1 (en) * 2015-03-27 2016-10-06 President And Fellows Of Harvard College Modified t cells and methods of making and using the same

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11879016B2 (en) 2014-03-06 2024-01-23 Autolus Limited Chimeric antigen receptor
US11434293B2 (en) 2017-06-09 2022-09-06 Autolus Limited Anti TRBC1 antigen binding domains
US11440961B2 (en) 2017-06-09 2022-09-13 Autolus Limited Anti TRBC1 antigen binding domains
US12516119B2 (en) 2017-06-09 2026-01-06 Autolus Limited Anti TRBC1 antigen binding domains

Also Published As

Publication number Publication date
DK3125934T3 (en) 2020-02-03
CN112094353A (en) 2020-12-18
CN106068276B (en) 2020-09-18
US20170334998A1 (en) 2017-11-23
RU2744046C2 (en) 2021-03-02
PH12016501646B1 (en) 2023-02-03
NZ761844A (en) 2021-06-25
MX2019013845A (en) 2020-02-24
KR20200027576A (en) 2020-03-12
PE20211887A1 (en) 2021-09-22
AU2019204921A1 (en) 2019-08-01
JP2020099356A (en) 2020-07-02
JP2017510257A (en) 2017-04-13
ES3033286T3 (en) 2025-08-01
SG11201606583VA (en) 2016-09-29
MX2019013846A (en) 2020-02-24
SG10201906460PA (en) 2019-09-27
HUE071755T2 (en) 2025-09-28
AU2019204921B2 (en) 2021-02-18
FI3241561T3 (en) 2025-07-07
CA2940564A1 (en) 2015-09-11
PH12016501646A1 (en) 2017-02-06
CN118852462A (en) 2024-10-29
DK3241561T3 (en) 2025-06-30
US20170066827A1 (en) 2017-03-09
CN112094347A (en) 2020-12-18
PE20170125A1 (en) 2017-03-16
AU2015225944A1 (en) 2016-09-01
PL3241561T3 (en) 2025-09-01
PH12020550203A1 (en) 2021-08-16
AU2015225944B2 (en) 2019-07-11
CU24475B1 (en) 2020-03-04
CL2019001567A1 (en) 2019-08-16
IL278879A (en) 2021-01-31
BR112016020304A2 (en) 2017-10-17
JP6767872B2 (en) 2020-10-14
NZ723307A (en) 2021-06-25
PT3125934T (en) 2019-12-16
KR20200027577A (en) 2020-03-12
AU2019204925A1 (en) 2019-08-01
IL278878B (en) 2022-07-01
CL2019001568A1 (en) 2019-08-16
CA2940564C (en) 2021-06-29
PL3125934T3 (en) 2020-04-30
EP3241561B1 (en) 2025-04-30
JP6767931B2 (en) 2020-10-14
MY173567A (en) 2020-02-04
PH12020550202A1 (en) 2022-03-07
RU2021101502A (en) 2021-06-25
JP2024074907A (en) 2024-05-31
BR112016020304B1 (en) 2024-02-27
KR102088082B1 (en) 2020-03-11
CN106068276A (en) 2016-11-02
PH12020550202B1 (en) 2023-11-15
HUE047641T2 (en) 2020-05-28
JP2017143838A (en) 2017-08-24
AU2019204921C1 (en) 2021-05-13
ES2758173T3 (en) 2020-05-04
AU2019204925B2 (en) 2021-02-18
RU2016138421A3 (en) 2018-07-25
EP3125934A1 (en) 2017-02-08
RU2018140694A (en) 2018-12-10
KR102235201B1 (en) 2021-04-05
IL278878A (en) 2021-01-31
JP2021184773A (en) 2021-12-09
EP4610654A2 (en) 2025-09-03
EP3125934B1 (en) 2019-10-23
EP3241561A1 (en) 2017-11-08
JP7149304B2 (en) 2022-10-06
WO2015132598A1 (en) 2015-09-11
RU2016138421A (en) 2018-04-05
NZ761848A (en) 2021-06-25
IL278879B1 (en) 2025-08-01
IL278879B2 (en) 2025-12-01
MX2016010856A (en) 2017-04-13
CL2018003096A1 (en) 2019-01-11
KR102235202B1 (en) 2021-04-05
PT3241561T (en) 2025-06-24
SG10201906461SA (en) 2019-09-27
IL247110A0 (en) 2016-09-29
KR20160127130A (en) 2016-11-02

Similar Documents

Publication Publication Date Title
CL2016002195A1 (en) Car chimeric antigen receptor with antigen binding domains to the constant region of the beta t cell receptor
MX376026B (en) CLAUDIN-6 SPECIFIC IMMUNORECEPTORS AND T CELL EPITOPES.
PH12017501039A1 (en) Antibodies targeting g-protein coupled receptor and methods of use
MX2017003640A (en) Chimeric antigen receptors.
IL262129A (en) Anti-cd25 gamma fc receptor bispecific antibodies for specific cell depletion of you
MX2021003704A (en) Heterodimeric antibodies that bind cd3 and tumor antigens.
IL252645B (en) Modified t cells - targeted chimeric antigen receptor cs1
DK3592379T3 (en) UNIVERSAL ANTI-CD22 CHIMERIC ANTIGEN RECEPTOR MODIFIED IMMUNE CELLS
MX389021B (en) CLAUDIN-18.2 SPECIFIC IMMUNORECEPTORS AND T CELL EPITOPES.
PH12018500710A1 (en) Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
MX2015017331A (en) ANTIBODIES ANTI FC SIMILAR TO RECEIVER 5 (FCRH5).
MX2017001079A (en) Bcma chimeric antigen receptors.
PL3183268T3 (en) Anti-CD123 chimeric antigen receptor (CAR) for use in the treatment of malignant neoplasm
MX383542B (en) B-CELL MATURATION ANTIGEN CHIMERIC ANTIGEN RECEPTORS.
DK3126380T3 (en) CHIMERIC ANTIGEN RECEPTOR SIGNAL SYSTEM (CAR)
ZA201906321B (en) Chimeric antigen receptor
GB201709508D0 (en) Chimeric antigen receptor
ZA202002044B (en) Monoclonal antibody to il-5rα
MX2016010499A (en) SYSTEMS AND METHODS FOR IDENTIFYING PROGESTERONE RECEPTOR SUBTIPOS.
GB201807862D0 (en) Chimeric antigen receptor
GB201721421D0 (en) Chimeric antigen receptor
GB201815775D0 (en) Chimeric antigen receptor
GB201809773D0 (en) Chimeric antigen receptor
GB201807866D0 (en) Chimeric antigen receptor
GB201721831D0 (en) T cell antigen receptor chimera